academic article

• Ofatumumab versus Teriflunomide in Multiple Sclerosis..  The New England journal of medicine.  383:546-557. 2020
• Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial..  JAMA neurology.  :-. 2020
• Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study..  Lancet.  391:1263-1273. 2018
• Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis..  The New England journal of medicine.  376:221-234. 2017
• Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis..  The New England journal of medicine.  376:209-220. 2017
• GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study..  Neurology.  72:806-812. 2009